[Creutzfeldt-Jakob disease, Heidenhain variant: case report with MRI (DWI) findings].
Creutzfeldt-Jakob disease (CJD) is a presenile dementia characterized by rapidly progressive mental deterioration, myoclonic jerking, and other less common neurological signs. Few autoctonous cases have been described in Brazil. A 54-year-old white woman, was admitted in our service with a month history of progressive, bilateral cortical blindness. After admission, she developed right partial motor seizures( right facial, upper and lower limbs), she became progressively aphasic( mixed aphasia). Seizures were controlled with phenytoin, but she developed choreoathetotic movements on her right dimidium, with partial control after introduction of chlorpromazine 25 mg q/d. She could no longer stand up or walk due to severe ataxia. The first EEG (October, 2001) showed left hemisphere severe seizure activity (status epilepticus partialis). She was delivered home with enteral nutrition, phenytoin, chlorpromazine and mepacrine 100 mg qd. The following laboratorial tests were negative or normal: blood series, platelets, ESR, kidney and liver function, copper, ceruloplasmin, VDRL, HIV, HTLV-1, lactate, and cerebral DSA (performed in other service).A spinal tap with normal opening pressure was perform and CSF examination was normal. CSF 14-3-3 protein was positive, CSF specific neuronal enolase 7.5 ng/ml(normal). Genetic study of PRNP gene did not disclosed any known mutation. A MRI (October, 2001) showed areas of hyperintense signal (T2 and FLAIR) without Gd-enhancement on T1, in the left temporal lobe and in both occipital lobes; basal ganglia have a normal appearance. DWI imaging showed bright areas at the same sites. An EEG (March, 2002) disclosed a periodical sharp triphasic waves pattern, suggestive of CJD. A second MRI (April, 2002) showed mild generalized atrophy, no ventricular dilatation, and the hyperintense sites disappeared. She remained clinically stable and under use of chlorpromazine and mepacrine until she died due to pulmonary complications on April, 2003.
Arruda
Walter Oleschko
WO
Instituto de Neurologia de Curitiba, Curitiba, PR, Brasil. warruda@speednet.com.br
Bordignon
Kelly C
KC
Milano
Jerônimo B
JB
Ramina
Ricardo
R
D000962:Antimalarials / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000627:therapeutic use; D015153:Blotting, Western; D007562:Creutzfeldt-Jakob Syndrome / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics; D038524:Diffusion Magnetic Resonance Imaging / Q000379:methods*; D004452:Echocardiography; D004569:Electroencephalography; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D009682:Magnetic Resonance Spectroscopy; D008875:Middle Aged; D010640:Phenothiazines / Q000627:therapeutic use; D018622:PrP 27-30 Protein / Q000235:genetics; D018621:PrPC Proteins / Q000235:genetics; D011796:Quinacrine / Q000627:therapeutic use
D000962:Antimalarials; D014150:Antipsychotic Agents; D010640:Phenothiazines; D018621:PrPC Proteins; D018622:PrP 27-30 Protein; D011796:Quinacrine